CRISPR Therapeutics proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors
- Crispr Therapeutics price target raised to $99 from $82 at Mizuho
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target raised to $66 from $57 at RBC Capital
- Crispr Therapeutics price target raised to $70 from $55 at Wells Fargo
